FAM
BBIO icon

Fulcrum Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Fulcrum Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$321K Buy
+4,456
New +$312K 0.03% 334

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Fulcrum Asset Management's BBIO Position: Q2 2026 in Review

Fulcrum Asset Management opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 4,456 shares worth $321K. The stake represents 0.03% of the portfolio and ranks #334 among its holdings.

474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Fulcrum Asset Management held 4,456 shares of BridgeBio Pharma worth $321K as of Q2 2026.
  • BridgeBio Pharma was a new Fulcrum Asset Management position in Q2 2026.
  • BridgeBio Pharma made up 0.03% of Fulcrum Asset Management's portfolio in Q2 2026, its #334 holding.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Fulcrum Asset Management's 13F filing for Q2 2026, filed 18 Aug 2026.